RT Journal Article
SR Electronic
T1 Metabolic programs define dysfunctional immune responses in severe COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.10.20186064
DO 10.1101/2020.09.10.20186064
A1 Thompson, Elizabeth A.
A1 Cascino, Katherine
A1 Ordonez, Alvaro A.
A1 Zhou, Weiqiang
A1 Vaghasia, Ajay
A1 Hamacher-Brady, Anne
A1 Brady, Nathan R.
A1 Sun, Im-Hong
A1 Wang, Rulin
A1 Rosenberg, Avi Z.
A1 Delannoy, Michael
A1 Rothman, Richard
A1 Fenstermacher, Katherine
A1 Sauer, Lauren
A1 Shaw-Saliba, Kathyrn
A1 Bloch, Evan M.
A1 Redd, Andrew D.
A1 Tobian, Aaron AR
A1 Horton, Maureen
A1 Smith, Kellie
A1 Pekosz, Andrew
A1 D’Alessio, Franco R.
A1 Yegnasubramanian, Srinivasan
A1 Ji, Hongkai
A1 Cox, Andrea L.
A1 Powell, Jonathan D.
YR 2020
UL http://medrxiv.org/content/early/2020/10/05/2020.09.10.20186064.abstract
AB It remains unclear why some patients infected with SARS-CoV-2 readily resolve infection while others develop severe disease. To address this question, we employed a novel assay to interrogate immune-metabolic programs of T cells and myeloid cells in severe and recovered COVID-19 patients. Using this approach, we identified a unique population of T cells expressing high H3K27me3 and the mitochondrial membrane protein voltage-dependent anion channel (VDAC), which were expanded in acutely ill COVID-19 patients and distinct from T cells found in patients infected with hepatitis c or influenza and in recovered COVID-19. Increased VDAC was associated with gene programs linked to mitochondrial dysfunction and apoptosis. High-resolution fluorescence and electron microscopy imaging of the cells revealed dysmorphic mitochondria and release of cytochrome c into the cytoplasm, indicative of apoptosis activation. The percentage of these cells was markedly increased in elderly patients and correlated with lymphopenia. Importantly, T cell apoptosis could be inhibited in vitro by targeting the oligomerization of VDAC or blocking caspase activity. In addition to these T cell findings, we also observed a robust population of Hexokinase II+ polymorphonuclear-myeloid derived suppressor cells (PMN-MDSC), exclusively found in the acutely ill COVID-19 patients and not the other viral diseases. Finally, we revealed a unique population of monocytic MDSC (M-MDSC) expressing high levels of carnitine palmitoyltransferase 1a (CPT1a) and VDAC. The metabolic phenotype of these cells was not only highly specific to COVID-19 patients but the presence of these cells was able to distinguish severe from mild disease. Overall, the identification of these novel metabolic phenotypes not only provides insight into the dysfunctional immune response in acutely ill COVID-19 patients but also provide a means to predict and track disease severity as well as an opportunity to design and evaluate novel metabolic therapeutic regimens.Competing Interest StatementJ.D.P. is a scientific founder, a paid consultant and has equity in Dracen Pharmaceuticals.Funding StatementFunding for this work was provided by a Johns Hopkins University Provost Research Grant, The Bill and Melinda Gates Foundation (134582), NIH Centers of Excellence in Influenza Research and Surveillance (HHSN272201400007C) and NIH (P41EB028239 to JDP). The study was supported in part by a cooperative agreement between Johns Hopkins University (JHU) and the Division of Intramural Research, NIAID, NIH, as well as extramural support from the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA; grant number IDSEP160031-01-00) and National Institute of Allergy and Infectious Diseases (R01AI120938, R01AI120938S1, R01AI128779, and U19A1088791). Contract HHSN272201400007C awarded to A.A.R.T the Johns Hopkins Center for Influenza Research and Surveillance (JHCEIRS) at the Johns Hopkins University. Confocal microscopy images acquired from Zeis LSM880 was supported by National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (S10OD023548 to JHUSOM Microscope Facility). The Core for Clinical Research Data Acquisition is supported in part by the Johns Hopkins Institute for Clinical and Translational Research (UL1TR001079).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Patients diagnosed with COVID-19 by positive SARS-CoV-2 RNA testing through the Johns Hopkins Healthcare System were enrolled in a protocol designed to generate a biospecimen repository linked to clinical data for investigation (Johns Hopkins Medicine (JHM) IRB 00245545) and another for analysis of research questions specific to immunology (JHM IRB 00255162). Following JHM IRB approval, PBMC samples were obtained under informed consent from: HCV infected patients (JHM IRB NA_0004638), hospitalized patients infected with influenza in 2019 (JHM IRB 00091667) and SARS-CoV-2 convalescent plasma donors (JHM IRB 00248402, JHM IRB 00250798)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available upon request.